Quantum Cyber (QUCY) H1 2026 earnings summary

Executive summary

• Transitioned from in-vitro diagnostics to AI and quantum-enabled autonomous systems, focusing on drones and defense applications.

• Divested colorectal cancer screening business, sold related assets, and rebranded as Quantum Cyber N.V.

• Launched Quantum Drones segment and secured key technology licenses and manufacturing assets.

Financial highlights

• No revenue from continuing operations for the quarter or six months ended June 30, 2026.

• Net loss from continuing operations was $11.0 million for the quarter and $16.1 million for the six months, compared to $3.5 million and $8.5 million, respectively, in the prior year.

• Operating expenses rose sharply to $9.9 million for the quarter and $12.4 million for the six months, driven by R&D and G&A related to the new business focus.

• Cash balance increased to $13.4 million as of June 30, 2026, up from $0.9 million at year-end 2025, due to equity and warrant financing.

Outlook and guidance

• Plans to invest in R&D and manufacturing for quantum drones and AI-enabled platforms.

• Management expects current cash and additional financing to cover planned expenditures for at least one year.

• Strategic focus on commercializing new technologies and scaling manufacturing capabilities.